samedan logo
 
 
spacer
home > pmps > spring 2017 > easy access
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Easy Access

Times have changed dramatically in the past 10 years, with external cost pressure, patent losses, dried-up R&D pipelines and the rise of biosimilars forcing Big Pharma to rethink its business models. All of a sudden, the cost of packaging drugs can make a telling difference to the bottom line, or even mean the difference between winning a tender or not.

All of this comes in an environment where patients are hoping for greater protection from external contamination, counterfeits and their children accessing dangerous drugs, and payers are expecting the industry to demonstrate the effectiveness of their products. But how can pharmaceutical companies balance the conflicting needs of lower cost and higher protection?

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Colin Reed is Marketing and Strategy Director for Amcor Flexibles Global Pharma and Medical EMEA businesses. He has 19 years of experience in pharmaceutical packaging and has held previous leadership positions in operations and marketing, including managing businesses in the Asia- Pacific region. Colin holds a Bachelor of Engineering degree and an MBA from Aston University, UK.

Greg Rosati is currently the Healthcare Marketing Director for Amcor Rigid Plastics. He has 24 years of packaging experience including 15 in healthcare and has held various leadership roles in product development, sales, marketing and quality systems. Greg holds a BS from Michigan State University, US.
spacer
Colin Reed
spacer
spacer
spacer
Greg Rosati
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cerba Research and ACT Genomics Announce Strategic Joint Venture CerbACT Asia

This expansion of the precision medicine offering includes central labs, flow cytometry, histopathology, and translational science laboratory services. Deep scientific expertise from both sides of this strategic alliance will support new growth areas for biotech and pharma clients globally and drive better patient outcomes across all phases of clinical trials.
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement